| Patient | Theodore Roosevelt |
|---|---|
| Date of birth | 2002-10-27 |
| Identifiers | MRN HR-NI012-SYN; SSN (made up) 000-12-6157 |
| Document date | 2026-06-08 |
| Author | Amos Kettering, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month asthma review with repeat spirometry. [S]
Mr. Roosevelt returns three months after starting maintenance-and-reliever therapy. Since the four-week review he has had no night waking and daytime symptoms about once a week. He uses one as-needed inhalation before training and rarely any other. He has not missed an evening dose since setting a reminder. The bedding covers are in place. His home peak flow has settled between 590 and 610 L/min, so 610 is his personal best. He is back to full boxing, rowing, and a long hill walk most weekends. No exacerbations, urgent visits, or oral corticosteroids. [S]
| Element | Detail |
|---|---|
| Interval change | No night waking; symptoms about once a week |
| Reliever use | One inhalation before training; rarely otherwise |
| Adherence | All maintenance doses taken since setting a reminder |
| Home peak flow | 590 to 610 L/min; personal best 610 |
| Function | Full training |
| Exacerbations | None since starting controller therapy |
| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No night cough or wheeze; breathless only at the end of hard rowing pieces |
| Ears, nose, mouth, and throat | Negative | No hoarseness or sore mouth |
| Musculoskeletal | Negative | No injuries from training |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two inhalations as needed for wheeze (bought after an urgent care visit; used most days before intake) | Two inhalations every 4 hours as needed | Respiratory tract route | 2025-12-15 to 2026-03-09 | stopped | S |
| Budesonide-formoterol 160/4.5 mcg inhaler, two inhalations twice daily for maintenance | Two inhalations twice daily, with a spacer, rinsing the mouth afterwards | Respiratory tract route | 2026-03-09 | active | S |
| Budesonide-formoterol 160/4.5 mcg inhaler, one inhalation as needed for symptoms and before exercise; no more than 12 inhalations a day in total | One inhalation as needed, repeated after a few minutes if needed; maximum 12 inhalations a day including maintenance doses | Respiratory tract route | 2026-03-09 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-08 | Body height | 175 | cm | S |
| 2026-06-08 | Body weight | 73 | kg | S |
| 2026-06-08 | Body mass index (BMI) [Ratio] | 23.8 | kg/m2 | S |
| 2026-06-08 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-06-08 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-06-08 | Heart rate | 70 | /min | S |
| 2026-06-08 | Respiratory rate | 14 | /min | S |
| 2026-06-08 | Body temperature | 36.6 | Cel | S |
| 2026-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-08 | FEV1 | 3.98 | L | >=3.65 L | Normal | S |
| 2026-06-08 | FEV1 measured/predicted | 89 | % | >=80% | Normal | S |
| 2026-06-08 | Forced vital capacity [Volume] Respiratory system | 5.02 | L | >=4.4 L | Normal | S |
| 2026-06-08 | FEV1/FVC | 0.79 | {ratio} | >=0.72 | Normal | S |
| 2026-06-08 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 605 | L/min | 80 percent or more of his personal best of 610 L/min (green zone) | Normal | S |
| 2026-06-08 | Total score [ACT] | 22 | {score} | S |
Vital signs recorded on 2026-06-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Mouth | No thrush |
| Lungs | Clear, with no wheeze on forced expiration |
| Inhaler technique | Correct with his own inhaler and spacer |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Moderate persistent asthma, uncontrolled at intake, with reversible airflow obstruction on spirometry; synthetic modern diagnosis linked to his documented lifelong asthma | active | confirmed | J45.40 | S — Synthetic modern classification confirmed by spirometry; the historical asthma is D and its persistence into adulthood is R. |
| Myopia, both eyes, corrected with glasses since boyhood | active | confirmed | H52.13 | S — Synthetic modern entry linked to his documented near-sightedness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 22, well controlled |
| Examination | Spirometry | At diagnosis, 3 to 6 months after stabilization, then every 1 to 2 years | Completed today | FEV1 3.98 L, 89 percent predicted; FEV1/FVC 0.79; FVC 5.02 L |
| Examination | Peak flow and personal best | Daily or with symptoms for moderate to severe asthma | Completed today | 605 L/min in clinic; personal best 610 L/min |
| Examination | Inhaler technique with his own device | Every visit | Completed today | Correct |
| Medication safety | Adherence and reliever use | Every visit | Completed today | Full adherence; reliever before training only |
| Survey | Exacerbation history | Every visit | Completed today | None since starting controller therapy |
| Self-management | Trigger and exposure review, smoking and vaping status | Every visit | Completed today | Bedding covers in place; never smoker |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Zones reset to the confirmed personal best |
| Survey | Step-up or step-down assessment | Every visit | Completed today | Controlled for about two months; reassess for step-down at the six-month review |
| Laboratory | FeNO and blood eosinophils | As indicated | Not indicated | Phenotyping completed at the four-week review; no diagnostic uncertainty |
| Referral | Biologic candidacy assessment | Only if severe and uncontrolled despite optimized Step 4 to 5 therapy | Not indicated | Well controlled at Step 4 |
| Medication safety | Vaccination status | Yearly | Up to date | PCV20 given at the four-week review; influenza vaccine due in the autumn |
Goal progress:
Guideline basis: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026)
Follow-up: Asthma review in three months, or within one week of any exacerbation. Next scheduled visit 2026-09-14: six-month asthma review after a summer exacerbation. [S]